Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways From Recent GLP-1 Research
- Newer multi-receptor GLP-1 agonists such as tirzepatide and retatrutide produce greater average weight loss than single-receptor agents like semaglutide in both clinical trials and real-world studies.1
- Retatrutide, the first triple-receptor agonist, has achieved mean weight loss exceeding 28% in phase 2 trials, approaching bariatric-surgery-level outcomes.1
- Lean-mass loss occurs across all GLP-1 agents and is best mitigated through structured resistance training and adequate protein intake rather than agent selection alone.
- Weight regain averages 60% within one year after stopping GLP-1 therapy, which highlights the need for long-term maintenance planning from the outset.1
- Adults considering GLP-1 therapy can schedule a personalized, lab-reviewed consultation at Mirror Plastic Surgery to receive a tailored protocol that accounts for metabolic health, body composition, and long-term goals.
How GLP-1 Strength for Weight Loss Varies by Receptor Targets
The weight-loss potency of GLP-1 receptor agonists increases as more receptors are engaged and as each receptor adds a complementary mechanism.
Single-receptor agonists (e.g., semaglutide) activate only the GLP-1 receptor. This action slows gastric emptying, stimulates glucose-dependent insulin secretion, suppresses glucagon release, and reduces hunger via central appetite centers. In landmark randomized controlled trials, semaglutide produced substantial total weight loss.1 A 2026 real-world study of adults with obesity found that continuous semaglutide use yielded weight loss at one year and at three years. These real-world results illustrate the adherence gap between trial settings and everyday practice.
To move beyond the ceiling of single-receptor agents, researchers developed dual-receptor medications. Dual-receptor agonists (e.g., tirzepatide) add GIP receptor activation, which amplifies insulin secretion in combination with GLP-1, shifts adipocyte metabolism toward fat oxidation, and improves insulin sensitivity in fat cells without affecting gastric emptying. Head-to-head SURMOUNT-5 data showed that tirzepatide produced greater mean weight loss at 72 weeks than semaglutide 2.4 mg.1 The same 2026 real-world study recorded weight loss at one year with continuous tirzepatide use.
Building on this, researchers introduced a third receptor target. Triple-receptor agonists (e.g., retatrutide) add glucagon receptor activation on top of GLP-1 and GIP. This addition increases energy expenditure via thermogenesis and hepatic lipid oxidation, an effect that single-target GLP-1 receptor agonists do not provide. In the TRIUMPH-1 trial presented at ADA 2026, retatrutide produced mean weight loss exceeding 28% (approximately 70 lbs) with 12 mg once-weekly dosing in adults with overweight or obesity without diabetes.1 These results mark the first medication outcomes that approach bariatric surgery in magnitude.
Retatrutide vs Ozempic (Semaglutide) for Weight Loss
On average weight-loss efficacy, retatrutide substantially outperforms semaglutide. Retatrutide achieves 20–24% weight loss in phase 2 trials at 48 weeks by combining GLP-1-mediated satiety, GIP-mediated nutrient partitioning, and glucagon-driven increases in energy expenditure.1 These results exceed semaglutide outcomes in equivalent trial conditions.
The tolerability profile requires a more careful look. Emerging triple agonists such as retatrutide show predominantly gastrointestinal adverse events that increase in a dose-related manner, with long-term safety still under evaluation in phase III trials as of 2026. Retatrutide is not yet FDA-approved, so it is not available as a branded prescription product. Its long-term safety dataset also remains smaller than that of semaglutide, which has years of post-market surveillance.
For patients who cannot tolerate semaglutide’s GI burden or who have plateaued on it, retatrutide’s additional mechanisms may offer a meaningful clinical step up. This escalation should occur only under close medical supervision with ongoing lab monitoring.
GLP-1 Choices for Weight Loss With Less Muscle Loss
Lean mass reduction accounts for a portion of total weight loss with GLP-1 receptor agonists and reflects the body’s adaptation to sustained negative energy balance. No currently available GLP-1 agent fully prevents lean-mass loss, yet several factors can reduce its extent.
The proportion of weight loss attributable to fat-free mass is broadly similar across selective GLP-1 receptor agonists and dual-incretin agonists such as tirzepatide, typically ranging from 25% to 40%.1 However, in the SURPASS-3 MRI substudy, patients taking tirzepatide showed reduced muscle fat infiltration, a marker of improved muscle quality, despite overall reduced muscle volume.
A 2026 randomized controlled trial found that patients with obesity on GLP-1 agonists improved body composition without a negative impact on muscular strength. Expert consensus statements published in 2025–2026 emphasize combining incretin-based pharmacotherapy with structured resistance exercise and adequate protein intake to minimize sarcopenia risk during GLP-1 receptor agonist treatment.
For patients with low baseline lean mass, older adults, or those with sarcopenic obesity, the greater absolute lean-tissue loss associated with tirzepatide’s larger total weight reduction remains clinically relevant. These patients benefit from individualized monitoring, including DXA scans and lab-guided protocols.
What Typically Happens After Stopping GLP-1 Drugs
Approximately 50% of patients discontinue GLP-1RA therapy within the first year, often due to adverse effects, insurance coverage limitations, or prescribing restrictions. Structured maintenance protocols that include lifestyle interventions, protein-adequate nutrition, and resistance training remain the primary tools for reducing regain after cessation.
Head-to-Head GLP-1 Comparison From 2024–2026 Trials
| Agent (Receptor Targets) | Weight Loss — Continuous Use, Real-World or Trial | GI Adverse Event Rate | Lean-Mass Share of Total Weight Lost |
|---|---|---|---|
| Semaglutide (GLP-1R) | Weight loss at 1 yr (real-world); substantial loss in landmark RCTs | 40–60% GI events, 5–10% discontinuation | Portion of total weight lost |
| Tirzepatide (GLP-1R + GIPR) | Weight loss at 1 yr (real-world); greater mean weight loss at 72 wks than semaglutide (SURMOUNT-5) | 50–70% GI events, 4–12% discontinuation | 25–40% of total weight lost |
| Retatrutide (GLP-1R + GIPR + GcgR) | >28% (TRIUMPH-1, ADA 2026); 20–24% at 48 wks (Phase 2) | Dose-related GI events, Phase III safety data pending | Phase III lean-mass data pending, consistent with class range |
How Patients and Clinicians Choose a GLP-1 Agent
Selecting the appropriate GLP-1 agent involves weighing multiple individualized factors rather than defaulting to the agent with the highest average trial weight loss. These factors fall into three broad categories: physiological compatibility, clinical monitoring needs, and practical constraints.
Physiological compatibility comes first. Tolerability determines whether a patient can stay on therapy long enough to see meaningful results. Patients with a history of GI sensitivity may respond better to a slower titration schedule or an agent with a more favorable GI profile at equivalent efficacy, such as tirzepatide relative to semaglutide at matched weight-loss benchmarks. Baseline body composition then guides the intensity of muscle-preservation strategies. Older adults or those with low lean mass benefit from DXA-confirmed body-composition monitoring and a structured resistance-training plan before and during therapy. Metabolic comorbidities such as insulin resistance, hepatic steatosis, and cardiovascular risk factors influence which receptor targets provide the most relevant secondary benefits beyond weight loss.
Clinical monitoring forms the second category. A thorough lab panel review that covers thyroid, liver, kidney, diabetes markers, and hormone panels identifies contraindications and establishes a personalized baseline for dose titration and safety monitoring. This baseline supports maintenance planning, which matters because weight regain often accelerates after discontinuation. A long-term maintenance strategy that includes lifestyle, nutrition, and potential transition protocols should be in place from the start.
Practical constraints complete the picture. Regulatory and availability status determines which agents a patient can actually access. FDA-approved branded agents, compounded formulations under narrowing 503A and 503B rules, and investigational agents such as retatrutide each carry distinct availability, quality-assurance, and legal considerations that may override purely clinical preferences.
Book an appointment with Ellie to receive a lab-reviewed, personalized GLP-1 protocol built around your metabolic profile, body-composition goals, and long-term maintenance plan.
Safety, Side Effects, and the Current Regulatory Landscape
Gastrointestinal adverse events such as nausea, vomiting, diarrhea, and constipation are the most frequently reported safety issues for GLP-1 receptor agonists and the principal cause of treatment discontinuation in obesity and type 2 diabetes trials. Tachyphylaxis to GI side effects typically occurs within 4–8 weeks at a stable dose through receptor desensitization, gastric motility adaptation, and central neural plasticity.
The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved on December 19, 2024, which triggered the phase-out of large-scale 503B compounded GLP-1 supply. The FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, finding no clinical need for outsourcing facilities to compound these drugs from bulk. The FDA has also issued warnings that many compounded semaglutide products use semaglutide sodium salt rather than the semaglutide base found in FDA-approved Ozempic and Wegovy, creating a chemically distinct compound with potential dosing accuracy and sterility risks.
Newer compounded formulations offered at Mirror Plastic Surgery represent a distinct category. These formulations are reported to carry a reduced GI side-effect burden, a lower likelihood of muscle wasting, and broader metabolic indications that include insulin resistance and cardiovascular risk factors. Because these agents are not FDA-regulated, sourcing from providers with rigorous batch testing and operating under medical supervision remains essential to patient safety.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 receptor agonist therapies, including compounded formulations, carry risks and must be used under qualified medical supervision. Regulatory status of compounded agents is subject to change; consult a licensed practitioner for current availability and individualized guidance. No outcomes are guaranteed.
Meet Your Practitioner: Ellie Pranckevicius, FNP-BC
Ellie Pranckevicius, FNP-BC, serves as the lead practitioner for peptide therapies and non-surgical aesthetics at Mirror Plastic Surgery. She holds a Bachelor’s in Health Science from Boston University and a Master’s in Nursing from the University of South Florida. She also spent four years in the Neuroscience ICU at Tampa General Hospital, experience that gives her a precise understanding of metabolic physiology, drug response, and the body’s capacity for recovery.
Her career began at a high-end medical spa in Boston, where she developed deep expertise in skin physiology and aesthetic assessment before pursuing her nurse practitioner credentials. At Mirror Plastic Surgery, Ellie combines that dual background to deliver GLP-1 and peptide protocols that are grounded in lab data, tailored to each patient’s physiology, and supported by concierge-level ongoing care. Patients receive direct access via text and telemedicine throughout the treatment journey.
Frequently Asked Questions About GLP-1 Peptides
- Are newer GLP-1 receptor agonist peptides better for weight loss than semaglutide?
On average, dual-receptor agonists such as tirzepatide and triple-receptor agonists such as retatrutide produce greater mean weight loss than semaglutide in both clinical trials and real-world studies. However, “better” depends on individual tolerability, baseline metabolic health, adherence, and whether a muscle-preservation strategy is in place. A patient who cannot tolerate the GI side effects of a higher-potency agent may achieve better net outcomes on a well-managed semaglutide protocol than on a poorly tolerated triple agonist.
No currently available GLP-1 agent eliminates lean-mass loss entirely. Across agents, roughly 20–40% of total weight lost comes from lean tissue. The most effective strategy for minimizing muscle loss is combining any GLP-1 therapy with structured resistance training and adequate daily protein intake. Body-composition monitoring via DXA scan before starting therapy and every six months thereafter allows for early detection and protocol adjustment. Ellie reviews these metrics as part of Mirror Plastic Surgery’s lab-guided peptide protocols.
Weight regain usually occurs after discontinuation. Research indicates that patients regain an average of 60% of lost weight within 52 weeks of stopping, with regain eventually plateauing at approximately 75% of the weight lost during treatment. This pattern supports the need to establish a maintenance plan that includes lifestyle, nutrition, and potentially a transition protocol before initiating therapy rather than treating GLP-1 agents as a short, finite course.
The regulatory landscape for compounded GLP-1s has narrowed significantly. Following the FDA’s resolution of the semaglutide and tirzepatide shortages in 2025, large-scale 503B outsourcing-facility compounding of these agents is being phased out. Section 503A patient-specific compounding may continue in narrow circumstances for documented individual clinical needs. The FDA has also flagged that some compounded products use a chemically distinct salt form of semaglutide, which raises dosing accuracy and sterility concerns. Patients considering any compounded GLP-1 formulation should proceed only under medical supervision with verified batch-tested sourcing.
Mirror Plastic Surgery’s approach begins with a 30–60 minute consultation with Ellie Pranckevicius that includes a full review of medical history, current medications, and lab panels covering thyroid, liver, kidney, diabetes markers, and hormone levels. From that data, Ellie builds a custom protocol rather than selecting a standardized dose from a menu. Ongoing support includes direct text access, telemedicine follow-ups, and protocol adjustments based on lab trends and body-composition data. Peptides are sourced from providers with rigorous batch testing, and the practice’s concierge model limits patient volume so each person receives sustained, individualized attention.
Final Takeaways for GLP-1 Weight-Loss Decisions
The evidence from 2025–2026 trials consistently shows that multi-receptor GLP-1 agonists produce greater average weight loss than single-receptor agents, with triple agonists such as retatrutide approaching bariatric-surgery-level outcomes in controlled settings. Real-world results remain lower than trial figures for all agents, largely because of adherence challenges and dose-escalation barriers. Lean-mass loss appears across the class and responds best to resistance training and adequate protein rather than agent selection alone. The substantial post-discontinuation weight regain documented in the Cambridge meta-analysis makes long-term maintenance planning a non-negotiable part of any responsible protocol. At the same time, the tightening regulatory environment for compounded GLP-1s raises the stakes for quality-assured, medically supervised sourcing.
For Tampa Bay–area adults navigating these decisions, a personalized, lab-reviewed consultation offers the most evidence-aligned path. This approach accounts for individual metabolic health, body composition, tolerability, and long-term goals instead of relying on a one-size-fits-all prescription.
Book an appointment with Ellie at Mirror Plastic Surgery in St. Petersburg to begin a medically supervised, lab-guided GLP-1 or peptide protocol tailored to your weight-loss and body-composition goals.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
